TCR2 Therapeutics Inc.
TCRR · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $99 | $77 | $52 | $37 |
| G&A Expenses | $24 | $23 | $17 | $14 |
| SG&A Expenses | $24 | $23 | $17 | $14 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $123 | $100 | $69 | $51 |
| Operating Income | -$153 | -$100 | -$69 | -$51 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $2 | $0 | $2 | $4 |
| Pre-Tax Income | -$152 | -$100 | -$67 | -$47 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$152 | -$100 | -$67 | -$48 |
| % Margin | – | – | – | – |
| EPS | -3.93 | -2.63 | -2.4 | -2.26 |
| % Growth | -49.4% | -9.6% | -6.2% | – |
| EPS Diluted | -3.93 | -2.63 | -2.4 | -2.26 |
| Weighted Avg Shares Out | 39 | 38 | 28 | 21 |
| Weighted Avg Shares Out Dil | 39 | 38 | 28 | 21 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2 | $0 | $2 | $0 |
| Interest Expense | $59 | $0 | $0 | $0 |
| Depreciation & Amortization | $64 | $3 | $2 | $1 |
| EBITDA | -$90 | -$97 | -$67 | -$51 |
| % Margin | – | – | – | – |